Pro-oncogenic role of alternative p38 mitogen-activated protein kinases p38γ and p38δ, linking inflammation and cancer in colitis-associated colon cancer

Cancer Research

Volumn 74, Issue 21, 2014, Pages 6150-6160

  Del Reino, Paloma ^a   Alsina Beauchamp, Dayanira ^a   Escós, Alejandra ^a   Cerezo Guisado, Ma Isabel ^a   Risco, Ana ^a   Aparicio, Noelia ^a   Zur, Rafal ^a   Fernandez Estévez, Marian ^a   Collantes, Elena ^b   Montans, Jose ^c   Cuenda, Ana ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Centro Anatomopatológico Camino de Vinateros   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 13;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL POPULATION; CELL PROLIFERATION; COLITIS; COLITIS ASSOCIATED COLON CANCER; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENZYME ANALYSIS; ENZYME MECHANISM; FEMALE; INTESTINE EPITHELIUM CELL; MACROPHAGE; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; CELL TRANSFORMATION; COLONIC NEOPLASMS; COMPLICATION; GENETICS; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; CARCINOGENESIS; CELL TRANSFORMATION, NEOPLASTIC; COLITIS; COLONIC NEOPLASMS; IMMUNITY, INNATE; INFLAMMATION; MACROPHAGES; MALE; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 12; MITOGEN-ACTIVATED PROTEIN KINASE 13;

EID: 84910020256     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0870     Document Type: Article

References (43)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 2009;6:297-305.
3. Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 2013;35:229-44.
4. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 2008;118:2516-25.
5. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6.
6. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007;1773:1358-75.
7. Remy G, Risco AM, Inesta-Vaquera FA, González-Terán B, Sabio G, Davis RJ, et al. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell Signal 2010;22:660-7.
8. Kang YJ, Chen J, Otsuka M, Mols J, Ren S, Wang Y, et al. Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation. J Immunol 2008;180:5075-82.
9. Kim C, Sano Y, Todorova K, Carlson BA, Arpa L, Celada A, et al. The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol 2008;9:1019-27.
10. Otsuka M, Kang YJ, Ren J, Jiang H, Wang Y, Omata M, et al. Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology 2010;138:1255-65, 65 e1-9.
11. Docena G, Rovedatti L, Kruidenier L, Fanning A, Leakey NA, Knowles CH, et al. Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in in flammatory bowel disease. Clin Exp Immunol 2010;162:108-15.
12. Zhao X, Kang B, Lu C, Liu S, Wang H, Yang X, et al. Evaluation of p38 MAPK pathway as a molecular signature in ulcerative colitis. J Proteome Res 2011;10:2216-25.
13. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122:7-14.
14. Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J 2004;18:1550-2.
15. Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:325-34.
16. ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002;50:507-12.
17. Ittner A, Block H, Reichel CA, Varjosalo M, Gehart H, Sumara G, et al. Regulation of PTEN activity by p38delta-PKD1 signaling in neutrophils confers inflammatory responses in the lung. J Exp Med 2012;209:2229-46.
18. Risco A, del Fresno C, Mambol A, Alsina-Beauchamp D, MacKenzie KF, Yang HT, et al. p38gamma and p38delta kinases regulate the Tolllike receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation. Proc Natl Acad Sci U S A 2012;109:11200-5.
19. Gonzalez-Teran B, Cortes JR, Manieri E, Matesanz N, Verdugo A, Rodríguez ME, et al. Eukaryotic elongation factor 2 controls TNF-alpha translation in LPS-induced hepatitis. J Clin Invest 2013;123:164-78.
20. Criado G, Risco A, Alsina-Beauchamp D, Perez-Lorenzo MJ, Escos A, Cuenda A. Alternative p38 mitogen-activated protein kinases are essential for collagen-induced arthritis. Arthritis Rheum 2014;66:1208-17.
21. Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013;13:679-92.
22. Risco A, Cuenda A. New Insights into the p38gamma and p38delta MAPK Pathways. J Signal Transduct 2012;2012:520289.
23. Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin MH, et al. p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res 2009;69:4648-55.
24. Qi X, Pohl NM, Loesch M, Hou S, Li R, Qin JZ, et al. p38alpha antagonizes p38gamma activity through c-Jun-dependent ubiquitinproteasome pathways in regulating Ras transformation and stress response. J Biol Chem 2007;282:31398-408.
25. Cerezo-Guisado MI, del Reino P, Remy G, Kuma Y, Arthur JS, Gallego-Ortega D, et al. Evidence of p38gamma and p38delta involvement in cell transformation processes. Carcinogenesis 2011;32:1093-9.
26. Sabio G, Arthur JS, Kuma Y, Peggie M, Carr J, Murray-Tait V, et al. p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. Embo J 2005;24:1134-45.
27. Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2007;2:1998-2004.
28. Neurath MF, Vehling D, Schunk K, Holtmann M, Brockmann H, Helisch A, et al. Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 2002;97:1978-85.
29. Koliaraki V, Roulis M, Kollias G. Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis. J Clin Invest 2012;122:4231-42.
30. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
31. Wang D, Dubois RN, Richmond A. The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol 2009;9:688-96.
32. Serebrennikova OB, Tsatsanis C, Mao C, Gounaris E, Ren W, Siracusa LD, et al. Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL-10 secretion and regulatory T-cell generation. Proc Natl Acad Sci U S A 2012;109:E1082-91.
33. Lawrenz M, Visekruna A, Kuhl A, Schmidt N, Kaufmann SH, Steinhoff U. Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease? Mucosal Immunol 2012;5:129-39.
34. Gantke T, Sriskantharajah S, Ley SC. Regulation and function of TPL-2, an IkappaB kinase-regulated MAP kinase kinase kinase. Cell Res 2011;21:131-45.
35. Bandow K, Kusuyama J, Shamoto M, Kakimoto K, Ohnishi T, Matsuguchi T. LPS-induced chemokine expression in both MyD88-dependent and -independent manners is regulated by Cot/Tpl2-ERK axis in macrophages. FEBS Lett 2012;586:1540-6.
36. Kakimoto K, Musikacharoen T, Chiba N, Bandow K, Ohnishi T, Matsuguchi T. Cot/Tpl2 regulates IL-23 p19 expression in LPS-stimulated macrophages through ERK activation. J Physiol Biochem 2010;66:47-53.
37. Rowley SM, Kuriakose T, Dockery LM, Tran-Ngyuen T, Gingerich AD, Wei L, et al. Tumor progression locus 2 (Tpl2) kinase promotes chemokine receptor expression and macrophage migration during acute inflammation. J Biol Chem 2014;289:15788-97.
38. Marsal J, Agace WW. Targeting T-cell migration in inflammatory bowel disease. J Intern Med 2012;272:411-29.
39. Axelsson LG, Landstrom E, Goldschmidt TJ, Gronberg A, Bylund-Fellenius AC. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+) -cell depleted, athymic, and NK-cell depleted SCID mice. Inflamm Res 1996;45:181-91.
40. Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM, Kondo T, Wada T, et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 2009;69:7884-92.
41. Shang K, Bai YP, Wang C, Wang Z, Gu HY, Du X, et al. Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS ONE 2012;7:e51848.
42. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009;16:368-77.
43. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329-42.